CLINICAL TRIALS PROFILE FOR DINOPROSTONE

All Clinical Trials for dinoprostone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00140114 ↗	Sublingual Versus Vaginal Misoprostol for Labor Induction at Term	Completed	American University of Beirut Medical Center	Phase 3	2004-01-01	Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. In contradistinction to prostaglandin E2 preparations (dinoprostone, Prepidil, Cervidil), misoprostol is inexpensive and available in scored tablets that can be broken and inserted vaginally. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance as both a labor induction and a cervical ripening agent. Such off-label indication has been endorsed by the American College of Obstetricians and Gynecologists and other medical bodies. Recently, FDA approved a new label for the use of cytotec during pregnancy which removed pregnancy as a contraindication for its use. Vaginal administration seems to be more efficacious than when given orally, although there is the worry of uterine tachysystole and hyperstimulation with vaginal doses > 50-µg. The use of sublingual misoprostol for cervical ripening at term was recently investigated in two studies that compared it to the oral route, on the assumption that the sublingual route would have the higher efficacy of the vaginal route by avoiding the first pass effects of the gastrointestinal and hepatic systems, while having lower hyperstimulation rates by avoiding the direct effects on the cervix. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the induction of labor at term. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00148473 ↗	Oral Versus Vaginal Misoprostol for Induction of Labor	Completed	Bangkok Metropolitan Administration Medical College and Vajira Hospital	Phase 2/Phase 3	2000-03-01	The purpose of this study is to compare the efficacy between a single dose of oral misoprostol 100 microgram and vaginal misoprostol 50 microgram for induction of labor.
NCT00299754 ↗	Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)	Completed	National Healthcare Group, Singapore	Phase 3	2003-01-01	Most studies of labour induction with misoprostol used doses higher than 25mg and intervals of 3-4 hours. We studied a low-dose regime of 25mg misoprostol and compared its efficacy as single dose or double dose with dosing interval of 6 hours to our current regime of 3 mg dinoprostone pessary.
NCT00299754 ↗	Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)	Completed	KK Women's and Children's Hospital	Phase 3	2003-01-01	Most studies of labour induction with misoprostol used doses higher than 25mg and intervals of 3-4 hours. We studied a low-dose regime of 25mg misoprostol and compared its efficacy as single dose or double dose with dosing interval of 6 hours to our current regime of 3 mg dinoprostone pessary.

Clinical Trial Conditions for dinoprostone

Condition Name

Condition Name for dinoprostone
Intervention	Trials
Cervical Ripening	16
Induction of Labor	12
Labor, Induced	6
Induction of Labor Affected Fetus / Newborn	6

Condition MeSH

Condition MeSH for dinoprostone
Intervention	Trials
Fetal Membranes, Premature Rupture	8
Rupture	7
Infertility	2
Premature Birth	2

Clinical Trial Locations for dinoprostone

Trials by Country

Trials by Country for dinoprostone
Location	Trials
United States	47
Egypt	22
Japan	13
Korea, Republic of	5
United Kingdom	4

Trials by US State

Trials by US State for dinoprostone
Location	Trials
Utah	3
Texas	2
Tennessee	2
South Carolina	2
Pennsylvania	2

Clinical Trial Progress for dinoprostone

Clinical Trial Phase

Clinical Trial Phase for dinoprostone
Clinical Trial Phase	Trials
PHASE4	2
PHASE1	1
Phase 4	23

Clinical Trial Status

Clinical Trial Status for dinoprostone
Clinical Trial Phase	Trials
Completed	45
Unknown status	15
Not yet recruiting	12

Clinical Trial Sponsors for dinoprostone

Sponsor Name

Sponsor Name for dinoprostone
Sponsor	Trials
Cairo University	18
Ferring Pharmaceuticals	8
Seoul National University Hospital	5

Sponsor Type

Sponsor Type for dinoprostone
Sponsor	Trials
Other	100
Industry	9

Last updated: May 1, 2026

DINOPROSTONE (Prostaglandin E2): Clinical Trials Update, Market Analysis, and 5-Year Projection

What is dinoprostone and where is it used commercially?

Dinoprostone is prostaglandin E2 (PGE2) used to induce cervical ripening and labor induction. Commercially, it is sold in multiple dosage forms aimed at obstetric use, including intracervical insert and oral/gel formulations (brand and product form vary by market). The therapy is used in time-sensitive inpatient settings where dosing schedules and administration procedures drive real-world utilization.

---

What is the clinical-trials update landscape for dinoprostone?

Dinoprostone is an established molecule with persistent but generally lower trial intensity versus newer obstetric agents. Most contemporary activity clusters around:

• Formulation and delivery optimization (release profile, ease of administration, time-to-effect)
• Comparative effectiveness and safety (against alternative prostaglandins or oxytocin-based approaches)
• Special-population evidence (still dominated by obstetric inclusion/exclusion parameters)

Clinical trial activity signals (global)

Across public registries, dinoprostone-related studies continue to be filed, including interventional comparisons and observational cohorts. Trial activity is typically concentrated in jurisdictions with robust obstetric trial networks and where prostaglandin formulations are already reimbursed.

Key structural characteristics of recent dinoprostone trials (pattern-level):

• Endpoints commonly include cervical change, time to delivery, and uterine tachysystole rates
• Comparators are often other prostaglandin regimens or labor induction pathways
• Safety reporting is centered on fetal and uterine adverse events

Operational implication for R&D: dinoprostone development is not about first-in-class innovation; it is about execution details (delivery system, regimen timing, patient throughput, and tolerability).

---

Where does dinoprostone sit in the competitive landscape?

What are the main competitive alternatives?

Dinoprostone competes primarily in obstetric labor induction and cervical ripening. Competitive product classes include:

• Other prostaglandins (including PGE1 analogs and other PGE formulations depending on geography)
• Oxytocin-based induction protocols
• Mechanical cervical ripening devices (balloon catheters) used as substitutes or adjuncts

Commercial reality: clinicians often choose based on perceived speed-to-effect, monitoring burden, contraindication profile, and local protocol habits. That makes product form and administrative workflow a commercial differentiator even when active ingredient is the same.

---

How does market demand translate into revenue mechanics?

What drives dinoprostone unit demand?

Demand correlates with:

• Pregnancy volumes and induction rates
• Guideline adoption for cervical ripening and induction
• Hospital protocol selection (influence of obstetric society guidance and local formularies)
• Availability constraints and tender cycles for government and integrated delivery networks

Where revenue is made

Revenue is driven by:

• Tender frequency and price pressure
• Product form share (insert vs gel vs oral)
• Storage and handling economics (institutional procurement and shelf logistics)

---

Market analysis by product form (business lens)

What product form factors affect share and pricing power?

Dinoprostone products are typically sold as branded or authorized generics depending on jurisdiction. Within dinoprostone portfolios, commercial performance depends on:

• Time-to-effect and ease of administration (nursing and workflow compatibility)
• Monitoring requirements (uterine activity surveillance burden)
• Dose controllability (repeatability and protocol integration)
• Safety profile communication (uterine tachysystole risk management)

---

Market analysis by geography (projection logic)

How do different regions behave?

• North America: tends to show strong protocol-driven demand; formulary and reimbursement dynamics dominate share.
• Europe: tender systems and guideline alignment shape unit movement; generic entry impacts ASP.
• Emerging markets: volume growth can be partially offset by procurement constraints and uneven distribution; adoption depends on hospital capability for monitoring.

Business model implication: the market is less about molecule growth and more about contract cycles and the relative usability of each formulation in local practice.

---

What are the 5-year market projections for dinoprostone?

Projection framework

Because dinoprostone is an established active ingredient, projections depend on:

• Induction prevalence growth (population and practice trends)
• Shift between induction modalities (mechanical vs pharmacologic and between prostaglandin products)
• Generic and tender-driven ASP compression
• Regulatory and supply continuity

Base-case, notional unit and revenue trajectory (directional)

Base-case (industry-normal):

• Units: low-to-mid single-digit CAGR
• ASP: mild-to-moderate decline driven by procurement and generics
• Revenue: flat to low positive growth with some regional uplift where tender rules favor established supply

Upside scenario:

• Adoption of prostaglandin-led cervical ripening protocols increases
• Delivery systems improve usability and shorten procedure workflow time
• Share gain from competitors facing supply or formulary displacement

Downside scenario:

• Shift toward mechanical devices reduces prostaglandin volume per induction case
• More aggressive price pressure at the tender level
• Supply continuity issues depress utilization

---

Key commercial metrics to track (to validate projection early)

1. Institutional formulary share by product form (insert vs gel)
2. Tender award cadence and average discount versus previous contracts
3. Estimated conversion rate from induction protocols (percentage of inductions that use dinoprostone)
4. Adverse event rate trends in post-market datasets (tachysystole-related labeling effects can move prescribing)
5. New generic/authorized product entries in target markets

---

Clinical and regulatory events that can move the market

What types of trial or regulatory outcomes matter most?

• Comparative trials with clinically meaningful operational endpoints (time-to-delivery, uterine activity management)
• Safety signals that can influence protocol restrictions
• Labeling updates tied to patient selection criteria
• Formulation modifications affecting release kinetics, administration workflow, or monitoring burden

Materiality threshold: evidence that changes induction pathways or procurement preference.

---

Key Takeaways

• Dinoprostone remains a protocol-driven, established obstetric product where commercial performance depends on product form usability, tender cycles, and formulary share, not on scientific novelty.
• Current clinical trial activity is concentrated in comparative and formulation/delivery optimization rather than first-in-class mechanisms.
• Market growth is likely modest and range-bound due to ASP compression from generics and procurement price pressure, with volume growth tied to induction prevalence and shifts within induction modality preferences.
• The most actionable early indicators are formulary share by form factor, tender pricing trends, and protocol conversion rates in target hospital networks.
• The most credible 5-year outlook is low-to-mid single-digit unit growth with flat-to-low positive revenue growth in base case, subject to regional procurement mechanics and induction modality mix.

---

FAQs

1. Is dinoprostone still the standard for cervical ripening and induction?
   Yes in many settings, with use guided by obstetric protocols and patient selection criteria.

2. What drives differentiation when the active ingredient is the same?
   Delivery system performance (release profile), administration workflow, monitoring burden, and institutional preference shaped by outcomes and safety reporting.

3. What trial endpoints most influence adoption?
   Cervical change timing, time-to-delivery, uterine tachysystole/monitoring outcomes, and safety in defined patient subgroups.

4. How do generics affect dinoprostone market growth?
   They typically reduce ASP through tender-based pricing while maintaining or modestly growing units depending on protocol persistence.

5. Which induction modalities compete most directly with dinoprostone?
   Other prostaglandin products and oxytocin protocols, with mechanical cervical ripening devices taking incremental share in some pathways.

---

References

[1] ClinicalTrials.gov. “Dinoprostone” (search results and study records). https://clinicaltrials.gov/
[2] WHO Model List of Essential Medicines. Prostaglandins and uterotonics entries (context on clinical role). https://www.who.int/medicines/publications/essential-medicines-lists
[3] FDA Drugs@FDA. Prostin (dinoprostone) and related product labeling records (where available). https://www.accessdata.fda.gov/scripts/cder/daf/
[4] EMA/European public assessment and product information portals (where applicable for dinoprostone products). https://www.ema.europa.eu/